Bioregulators Peptides

Also: Epitalon, Epithalone

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), modeled on a natural pineal gland extract. It came out of decades of Russian gerontology research led by Vladimir Khavinson and is marketed as an anti-aging compound that supposedly switches telomerase back on. It has no approval from the FDA, EMA, or other Western regulators, and the human evidence is thin.

Also: Thymic Factor, Thymus Extract

Thymalin is not a single peptide but a polypeptide complex extracted from calf thymus, developed in the Soviet and Russian peptide-bioregulator tradition associated with Vladimir Khavinson. It is used in Russia and several post-Soviet countries to correct immune deficiency and is promoted as a geroprotector, with claimed effects on T and B lymphocytes, infection rates and aging. Outside that region it has no FDA or EMA approval, and the strongest human data come from a small number of studies, several from the originating research groups.

Also: EDR, Glu-Asp-Arg

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (the EDR peptide), from the Russian peptide-bioregulator family designed to mimic short signaling peptides found in brain tissue. It is studied as a neuroprotective and antioxidant compound, with researchers proposing it protects neurons from oxidative stress and supports cognition. Be clear-eyed about the evidence: it is essentially all cell-culture and animal work from a small set of related labs, with no human clinical trials and no regulatory approval.

Also: Lys-Glu, KE Dipeptide

Vilon is a synthetic dipeptide, Lys-Glu (lysine-glutamic acid), one of the short peptide bioregulators developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is marketed in the anti-aging and immune-support space as a thymus-related bioregulator, but the real evidence base is almost entirely Russian animal studies. There are no registered Western randomized human clinical trials, so any human claims should be read with heavy skepticism.

Also: Ala-Glu-Asp, AED Tripeptide

Cartalax is a synthetic tripeptide (Ala-Glu-Asp, or AED) from the Khavinson family of short peptide bioregulators, studied as a cartilage and connective-tissue regulator. It is a research compound, not an approved drug, and no registered human clinical trials exist.

Also: Lys-Glu-Asp-Ala, KEDA

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.

Also: Glu-Asp-Leu, EDL

Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.

Also: Ala-Glu-Asp-Pro, AEDP

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.

Also: Lys-Glu-Asp, KED

Vesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.

Also: Glu-Asp-Gly, EDG

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.

Also: Glu-Asp-Pro, EDP

Crystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).

Prostamax is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Pro, KEDP) marketed as a prostate bioregulator, conceived as the defined-sequence successor to the older bovine prostate extracts Prostatilen and Vitaprost. It is studied for prostate inflammation and age-related prostate changes, and it has no FDA or EMA approval. Most of the actual clinical prostate evidence belongs to the parent extract, not to the synthetic KEDP peptide itself.

Testagen is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Gly, KEDG) marketed as a testicular bioregulator for male reproductive and hormonal support. It is one of the more obscure peptides in the family, with almost no peer-reviewed human data and no FDA or EMA approval. What exists is a single small Russian clinical report plus the general Khavinson gene-regulation theory, so confidence in any specific claim is low.

Thyreogen is not a single drug peptide but a 'cytomax' supplement - a mix of short peptides extracted from calf thyroid tissue, sold as part of Professor Vladimir Khavinson's Russian bioregulator line and marketed for thyroid support. There is no defined sequence on the label, no FDA approval, and no independent peer-reviewed clinical trial behind it. Treat the marketing claims as unproven.

Ventfort is a Khavinson-line 'cytomax' supplement made from a peptide complex extracted from calf blood vessel tissue, sold under the code A-3 and marketed for vascular and circulatory support. It has no published amino acid sequence, no FDA approval, and no independent randomized human trials. The benefit claims are vendor claims, not established medicine.

Veslugen is the vendor spelling for Vesugen, a synthetic tripeptide with the sequence Lys-Glu-Asp (KED) from Vladimir Khavinson's Russian bioregulator program, studied as a vascular 'bioregulator.' Unlike the crude tissue-extract cytomaxes, KED is a single defined molecule (formula C15H26N4O8, around 390 Da). It has named mechanistic studies but no registered randomized human trials and no regulatory approval.

Also: Ala-Glu-Asp-Leu, AEDL

Bronchogen is a synthetic tetrapeptide bioregulator from the Khavinson family, usually written as Ala-Glu-Asp-Leu (the original lab paper used the order Ala-Asp-Glu-Leu, ADEL). It was designed to model peptides found in lung and bronchial tissue and is studied for respiratory cell repair and age-related lung decline. There are no approvals and no registered human clinical trials. Almost all of the real data is laboratory work in cell cultures.